Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00875875

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
The University of Texas Health Science Center, Houston · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2. a single 600 mg dose of rifaximin daily for 3 days.

Conditions

Interventions

TypeNameDescription
DRUGRifaximinRifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days

Timeline

Start date
2009-06-01
Primary completion
2009-06-01
Completion
2009-06-01
First posted
2009-04-06
Last updated
2015-06-10

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT00875875. Inclusion in this directory is not an endorsement.